Patent 4,711,880 (US 4,711,880): scope of claims, crystalline-form protection, and US patent landscape for disodium 3-amino-1-hydroxypropane-1,1-diphosphonate

US 4,711,880 is a US crystalline-form patent centered on the API disodium 3-amino-1-hydroxypropane-1,1-diphosphonate (a 3-amino-1-hydroxypropane-1,1-diphosphonate disodium salt) defined by (i) inclusion of water of crystallisation, (ii) specific water-content and hydrate identities, (iii) crystallisation and drying process constraints, (iv) X-ray powder diffraction (XRPD) lattice-spacing “fingerprints,” and (v) an enteral pharmaceutical-preparation use claim tied to the claimed crystalline form. The estate’s infringement risk for competitors concentrates on manufacturing routes and release specifications that result in the same crystalline, water-bearing forms and, for claim 8, matches the XRPD pattern parameters.

What does US 4,711,880 claim cover for disodium 3-amino-1-hydroxypropane-1,1-diphosphonate?

Answer (claim scope in one line): A crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate containing water of crystallisation, with downstream coverage of specific hydrate/water content, production conditions that yield the crystal form, and enteral drug products containing that form.

Core product definition: water-containing crystalline form

Claim 1 is the broad anchor: it covers the API in a crystalline form containing water of crystallisation, without restricting which hydrate number or exact water percentage.

API: disodium 3-amino-1-hydroxypropane-1,1-diphosphonate
Condition: crystalline form with water of crystallisation
No explicit XRPD thresholds in claim 1 (those appear later in claim 8).

Narrower water-content sub-range (Claim 2)

Claim 2 limits claim 1 to a specific water content range:

~24.1% to ~24.5% by weight.

This is an enforceable “spec-driven” definition: a commercial batch falling outside the stated water-content window may avoid claim 2, even if it is still a water-bearing crystalline form.

Specific hydrate identity (Claim 3)

Claim 3 narrows to:

crystalline pentahydrate form.

So the patent estate has at least two “modes” of identification:

by hydrate number (pentahydrate), and
by measured water content (24.1-24.5 wt%).

Process-by-crystallisation and drying route constraints (Claims 4–7)

Claims 4–7 define the crystalline form using manufacturing conditions that a defendant would need to replicate to practice the claim. Practically, these constraints shape validity and infringement analysis because they tie the protected solid form to particular process windows.

Claim 4: crystallisation from a water-containing solution, followed by drying at “normal or slightly elevated temperature.”
Claim 5: crystallisation from at least saturated aqueous solution, crystal formation at ≥ ~50°C, then drying at 15–60°C.
Claim 6: crystallisation from at least saturated aqueous solution, crystal formation at ~50–80°C, then drying at either 18–25°C or 35–40°C.
Claim 7: crystallisation by exposure to moist air:
- relative humidity ~95–99%
- at ~20–25°C.

These claims create an additional attack surface: if competitors produce the same pentahydrate (or the same XRPD pattern) via different process conditions, infringement may still depend on whether the solid form itself is present (product claims) versus whether only the process claims are at issue.

Structural “fingerprint” coverage via XRPD (Claim 8)

Claim 8 further tightens claim 1 to a crystalline material characterized by an XRPD powder pattern under defined measurement settings:

Guinier-de-Wolff camera
copper Kα radiation source
matched set of d-values and relative line intensities.

This is the most technical and evidentiary-demanding claim because it requires measurement of peak positions and intensity ranking. It also can be leveraged in infringement and invalidity arguments depending on how strictly “matching” is interpreted.

Downstream formulation coverage: enteral preparations (Claim 9)

Claim 9 covers:

pharmaceutical preparations intended for enteral administration to warm-blooded animals
containing the API in the claimed crystalline form (claim 1 form).

This is not a method-of-use claim for therapy or indication. It is a product-including claim tied to the solid form and a route-of-administration category (enteral) for animals.

How do Claims 2–8 narrow the crystalline form protected by US 4,711,880?

Water-content gating (Claim 2)

Water content: ~24.1–~24.5 wt%.

Practical litigation implication: defendants can potentially design around by producing a different hydrate form or a water-bearing polymorph with outside water content, then validate via Karl Fischer (or equivalent) and XRPD.

Hydrate identity gating (Claim 3)

“Crystalline pentahydrate form.”

This creates a clearer design-around target:

avoid the pentahydrate solid form while still providing the API (or provide a different hydrate or anhydrous form).

Process windows (Claims 4–7)

Claim 4 is relatively broad on drying (“normal or slightly elevated temperature”), so it is harder to design around.
Claims 5–7 are more constraining and provide clearer “process carve-out” options.

XRPD match gate (Claim 8)

Claim 8 lists many d-values and intensity descriptors. The “fingerprint” requires a specific diffraction pattern, including:

very strong peaks (e.g., at 9.2 Å; 5.91 Å; 5.02 Å; 4.97 Å; 4.63 Å is “very weak,” etc.)
peaks described as “medium,” “strong,” “weak,” “very weak.”

Key d-values shown in claim 8 (Å):

10.2, 9.9, 9.2, 5.91, 5.57, 5.42, 5.30, 5.14, 5.02, 4.97, 4.63, 4.41, 4.16, 4.07, 4.04, 3.95, 3.75, 3.67, 3.63, 3.61, 3.58, 3.51, 3.43, 3.38, 3.15, 3.14, 3.09, 3.03, 3.01, 2.98, 2.97, 2.91, 2.82, 2.80, 2.78, 2.75, 2.73, 2.71, 2.69, 2.67, 2.66, 2.63, 2.62, 2.61, 2.58, 2.57.

The claim is rigid: it is not framed as “substantially similar” in the text provided. That matters for infringement (strict matching) and validity (obviousness/anticipation based on earlier XRPD data).

What are the practical infringement pathways for US 4,711,880 in the US?

1) Product presence: making and selling the same hydrate/crystalline form

If a competitor supplies disodium 3-amino-1-hydroxypropane-1,1-diphosphonate that is a crystalline material containing water of crystallisation, it risks claim 1.

If that material is specifically pentahydrate with 24.1–24.5 wt% water or matches the XRPD pattern, it risks claims 2, 3, and 8.

2) Process-linked enforcement: manufacturing conditions

Claims 4–7 can be asserted where the accused process yields the same solid form under the claimed crystallisation and drying conditions. Even if the final product is the same crystalline material, process constraints can be litigated via discovery into batch records, drying curves, RH logs, and crystallisation temperature profiles.

3) Downstream formulations: enteral animal products

Claim 9 targets warm-blooded animals and enteral administration. A generic or competitor selling an enteral veterinary formulation containing the protected crystalline form can fall within claim 9 even if their animal-formulation excipients differ, since the “characterised in that” element ties to API solid form.

How could competitors design around US 4,711,880?

Design-around levers aligned to the claim structure

Change hydrate state: avoid pentahydrate and produce a different hydrate/solvate/anhydrous form.
Shift water content: move outside ~24.1–24.5 wt% range (if still a crystalline form with some water, claim 1 can remain a risk, but claim 2 can drop out).
Change XRPD fingerprint: produce a solid form that does not match claim 8’s d-value set and intensity profile.
Modify crystallisation/drying/RH windows: avoid the specific temperature and RH ranges tied to claims 5–7 (while recognising claim 1’s broader product definition still matters).
Formulation pathway: keep the API crystalline form distinct from the claim 1 form to avoid claim 9.

What US patent-expiration timeline applies to US 4,711,880?

No filing/priority date, prosecution history, or term adjustments are provided in the prompt, so an exact US expiration date cannot be derived from the data supplied. The analysis below focuses on claim scope and landscape logic rather than calendaring.

How does the patent landscape for this asset typically look in the US for crystalline-form APIs like this?

A crystalline-form patent like US 4,711,880 usually sits within an ecosystem of related IP layers:

earlier disclosures of the API in general (composition/solid forms),
later disclosures of specific hydrates/polymorphs/solvates,
process patents around crystallisation, drying, and water control,
formulation patents (dosage forms, excipients, enteral products),
analytic-method patents (XRPD methods, Raman, DSC, hydrate quantification).

Within that ecosystem, US 4,711,880’s claim set is strongest against defendants whose commercial solids match the patented water-bearing crystalline material, including pentahydrate identity and the specified XRPD pattern.

Where are the biggest validity and enforceability pressure points in US 4,711,880’s claim language?

XRPD claim tightness vs measurement variability (Claim 8)

Claim 8 uses a detailed list of d-values and intensity categories. In litigation, this invites disputes on:

calibration and instrument settings,
peak picking resolution,
whether the intensity ranking is categorical (“very strong” vs “strong”) or should be treated numerically,
inter-lab reproducibility.

As written, claim 8 is a high-specificity claim, which can cut both ways: it narrows coverage but gives a precise infringement target.

Process claims rely on “obtainable by”

Claims 4–7 are framed as “obtainable by” crystallisation/drying processes. The enforceability of such claims often turns on whether a court treats them as:

process limitations that require those steps, or
functional statements that still get reduced to the identity of the final solid form.

Product claims depend on water-of-crystallisation characterization

Claims 1–3 depend on demonstrating that the sold or manufactured material is crystalline and contains water of crystallisation, and (for claim 2) that the water content lands within a narrow band.

What does US 4,711,880 cover commercially (product category and route)?

Claim 9 is not human-only

Claim 9 is limited to:

enteral administration
warm-blooded animals

This suggests the patent is positioned for veterinary or animal health markets rather than human-specific NDA/ANDA workflows.

Solid-form strategy matters for commercial launch readiness

Any commercial scale crystallisation step that controls:

hydration state
residual water
exposure humidity during handling
drying step endpoint

can be the difference between avoiding and triggering claims 1–3 and 8.

Key Takeaways

US 4,711,880 protects a specific class of water-of-crystallisation-containing crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate, with layered narrowing via (i) ~24.1–24.5 wt% water, (ii) pentahydrate identity, (iii) crystallisation/drying/RH process windows, and (iv) a detailed XRPD diffraction “fingerprint.”
Strongest design-around options are to produce a different hydrate/solid form that fails claim 2 (water content band), claim 3 (not pentahydrate), and/or claim 8 (XRPD mismatch).
Process constraints in claims 4–7 create additional infringement and discovery hooks through temperature profiles and humidity exposure logs.
Claim 9 expands to enteral animal formulations containing the patented crystalline form.

FAQs

1) What crystalline solid identifiers matter most for US 4,711,880 infringement?

XRPD match under Guinier-de-Wolff with copper Kα (claim 8) and measured water content (~24.1–24.5 wt%, claim 2), plus pentahydrate identity (claim 3).

2) Can a competitor avoid claim 2 by shifting residual water slightly?

Yes, shifting water content outside ~24.1–24.5 wt% can avoid claim 2, though claim 1 may still apply if the material remains a water-of-crystallisation crystalline form.

3) If a competitor makes the same pentahydrate via different process conditions, does that avoid claims 5–7?

It may avoid the specific “obtainable by” process limitations in claims 5–7, but the presence of the protected crystalline form still risks claims 1–3 and 8.

4) Does claim 9 cover human enteral products?

Claim 9 is limited to “warm-blooded animals,” so it is not drafted for a human-only scope.

5) Which claim is most likely to require technical solid-state characterization evidence?

Claim 8, because it is anchored to XRPD d-values and relative intensity descriptors.

References (APA)

United States Patent 4,711,880.

Title:	Crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
Abstract:	The invention relates to a novel crystal modification, containing water of crystallization, of disodium 3-amino-1-hydroxypropane-1,1-diphosphonate of the formula and to a process for the manufacture thereof. This modification is suitable for the oral treatment of disorders of the calcium and phosphate metabolism and associated diseases in warm-blooded animals.
Inventor(s):	Peter H. Stahl, Beat Schmitz
Assignee:	Henkel AG and Co KGaA , Novartis Corp
Application Number:	US06/905,097
Patent Claim Types: see list of patent claims	Formulation; Compound;
Patent landscape, scope, and claims:	Patent 4,711,880 (US 4,711,880): scope of claims, crystalline-form protection, and US patent landscape for disodium 3-amino-1-hydroxypropane-1,1-diphosphonate US 4,711,880 is a US crystalline-form patent centered on the API disodium 3-amino-1-hydroxypropane-1,1-diphosphonate (a 3-amino-1-hydroxypropane-1,1-diphosphonate disodium salt) defined by (i) inclusion of water of crystallisation, (ii) specific water-content and hydrate identities, (iii) crystallisation and drying process constraints, (iv) X-ray powder diffraction (XRPD) lattice-spacing “fingerprints,” and (v) an enteral pharmaceutical-preparation use claim tied to the claimed crystalline form. The estate’s infringement risk for competitors concentrates on manufacturing routes and release specifications that result in the same crystalline, water-bearing forms and, for claim 8, matches the XRPD pattern parameters. What does US 4,711,880 claim cover for disodium 3-amino-1-hydroxypropane-1,1-diphosphonate? Answer (claim scope in one line): A crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate containing water of crystallisation, with downstream coverage of specific hydrate/water content, production conditions that yield the crystal form, and enteral drug products containing that form. Core product definition: water-containing crystalline form Claim 1 is the broad anchor: it covers the API in a crystalline form containing water of crystallisation, without restricting which hydrate number or exact water percentage. API: disodium 3-amino-1-hydroxypropane-1,1-diphosphonate Condition: crystalline form with water of crystallisation No explicit XRPD thresholds in claim 1 (those appear later in claim 8). Narrower water-content sub-range (Claim 2) Claim 2 limits claim 1 to a specific water content range: ~24.1% to ~24.5% by weight. This is an enforceable “spec-driven” definition: a commercial batch falling outside the stated water-content window may avoid claim 2, even if it is still a water-bearing crystalline form. Specific hydrate identity (Claim 3) Claim 3 narrows to: crystalline pentahydrate form. So the patent estate has at least two “modes” of identification: by hydrate number (pentahydrate), and by measured water content (24.1-24.5 wt%). Process-by-crystallisation and drying route constraints (Claims 4–7) Claims 4–7 define the crystalline form using manufacturing conditions that a defendant would need to replicate to practice the claim. Practically, these constraints shape validity and infringement analysis because they tie the protected solid form to particular process windows. Claim 4: crystallisation from a water-containing solution, followed by drying at “normal or slightly elevated temperature.” Claim 5: crystallisation from at least saturated aqueous solution, crystal formation at ≥ ~50°C, then drying at 15–60°C. Claim 6: crystallisation from at least saturated aqueous solution, crystal formation at ~50–80°C, then drying at either 18–25°C or 35–40°C. Claim 7: crystallisation by exposure to moist air: relative humidity ~95–99% at ~20–25°C. These claims create an additional attack surface: if competitors produce the same pentahydrate (or the same XRPD pattern) via different process conditions, infringement may still depend on whether the solid form itself is present (product claims) versus whether only the process claims are at issue. Structural “fingerprint” coverage via XRPD (Claim 8) Claim 8 further tightens claim 1 to a crystalline material characterized by an XRPD powder pattern under defined measurement settings: Guinier-de-Wolff camera copper Kα radiation source matched set of d-values and relative line intensities. This is the most technical and evidentiary-demanding claim because it requires measurement of peak positions and intensity ranking. It also can be leveraged in infringement and invalidity arguments depending on how strictly “matching” is interpreted. Downstream formulation coverage: enteral preparations (Claim 9) Claim 9 covers: pharmaceutical preparations intended for enteral administration to warm-blooded animals containing the API in the claimed crystalline form (claim 1 form). This is not a method-of-use claim for therapy or indication. It is a product-including claim tied to the solid form and a route-of-administration category (enteral) for animals. How do Claims 2–8 narrow the crystalline form protected by US 4,711,880? Water-content gating (Claim 2) Water content: ~24.1–~24.5 wt%. Practical litigation implication: defendants can potentially design around by producing a different hydrate form or a water-bearing polymorph with outside water content, then validate via Karl Fischer (or equivalent) and XRPD. Hydrate identity gating (Claim 3) “Crystalline pentahydrate form.” This creates a clearer design-around target: avoid the pentahydrate solid form while still providing the API (or provide a different hydrate or anhydrous form). Process windows (Claims 4–7) Claim 4 is relatively broad on drying (“normal or slightly elevated temperature”), so it is harder to design around. Claims 5–7 are more constraining and provide clearer “process carve-out” options. XRPD match gate (Claim 8) Claim 8 lists many d-values and intensity descriptors. The “fingerprint” requires a specific diffraction pattern, including: very strong peaks (e.g., at 9.2 Å; 5.91 Å; 5.02 Å; 4.97 Å; 4.63 Å is “very weak,” etc.) peaks described as “medium,” “strong,” “weak,” “very weak.” Key d-values shown in claim 8 (Å): 10.2, 9.9, 9.2, 5.91, 5.57, 5.42, 5.30, 5.14, 5.02, 4.97, 4.63, 4.41, 4.16, 4.07, 4.04, 3.95, 3.75, 3.67, 3.63, 3.61, 3.58, 3.51, 3.43, 3.38, 3.15, 3.14, 3.09, 3.03, 3.01, 2.98, 2.97, 2.91, 2.82, 2.80, 2.78, 2.75, 2.73, 2.71, 2.69, 2.67, 2.66, 2.63, 2.62, 2.61, 2.58, 2.57. The claim is rigid: it is not framed as “substantially similar” in the text provided. That matters for infringement (strict matching) and validity (obviousness/anticipation based on earlier XRPD data). What are the practical infringement pathways for US 4,711,880 in the US? 1) Product presence: making and selling the same hydrate/crystalline form If a competitor supplies disodium 3-amino-1-hydroxypropane-1,1-diphosphonate that is a crystalline material containing water of crystallisation, it risks claim 1. If that material is specifically pentahydrate with 24.1–24.5 wt% water or matches the XRPD pattern, it risks claims 2, 3, and 8. 2) Process-linked enforcement: manufacturing conditions Claims 4–7 can be asserted where the accused process yields the same solid form under the claimed crystallisation and drying conditions. Even if the final product is the same crystalline material, process constraints can be litigated via discovery into batch records, drying curves, RH logs, and crystallisation temperature profiles. 3) Downstream formulations: enteral animal products Claim 9 targets warm-blooded animals and enteral administration. A generic or competitor selling an enteral veterinary formulation containing the protected crystalline form can fall within claim 9 even if their animal-formulation excipients differ, since the “characterised in that” element ties to API solid form. How could competitors design around US 4,711,880? Design-around levers aligned to the claim structure Change hydrate state: avoid pentahydrate and produce a different hydrate/solvate/anhydrous form. Shift water content: move outside ~24.1–24.5 wt% range (if still a crystalline form with some water, claim 1 can remain a risk, but claim 2 can drop out). Change XRPD fingerprint: produce a solid form that does not match claim 8’s d-value set and intensity profile. Modify crystallisation/drying/RH windows: avoid the specific temperature and RH ranges tied to claims 5–7 (while recognising claim 1’s broader product definition still matters). Formulation pathway: keep the API crystalline form distinct from the claim 1 form to avoid claim 9. What US patent-expiration timeline applies to US 4,711,880? No filing/priority date, prosecution history, or term adjustments are provided in the prompt, so an exact US expiration date cannot be derived from the data supplied. The analysis below focuses on claim scope and landscape logic rather than calendaring. How does the patent landscape for this asset typically look in the US for crystalline-form APIs like this? A crystalline-form patent like US 4,711,880 usually sits within an ecosystem of related IP layers: earlier disclosures of the API in general (composition/solid forms), later disclosures of specific hydrates/polymorphs/solvates, process patents around crystallisation, drying, and water control, formulation patents (dosage forms, excipients, enteral products), analytic-method patents (XRPD methods, Raman, DSC, hydrate quantification). Within that ecosystem, US 4,711,880’s claim set is strongest against defendants whose commercial solids match the patented water-bearing crystalline material, including pentahydrate identity and the specified XRPD pattern. Where are the biggest validity and enforceability pressure points in US 4,711,880’s claim language? XRPD claim tightness vs measurement variability (Claim 8) Claim 8 uses a detailed list of d-values and intensity categories. In litigation, this invites disputes on: calibration and instrument settings, peak picking resolution, whether the intensity ranking is categorical (“very strong” vs “strong”) or should be treated numerically, inter-lab reproducibility. As written, claim 8 is a high-specificity claim, which can cut both ways: it narrows coverage but gives a precise infringement target. Process claims rely on “obtainable by” Claims 4–7 are framed as “obtainable by” crystallisation/drying processes. The enforceability of such claims often turns on whether a court treats them as: process limitations that require those steps, or functional statements that still get reduced to the identity of the final solid form. Product claims depend on water-of-crystallisation characterization Claims 1–3 depend on demonstrating that the sold or manufactured material is crystalline and contains water of crystallisation, and (for claim 2) that the water content lands within a narrow band. What does US 4,711,880 cover commercially (product category and route)? Claim 9 is not human-only Claim 9 is limited to: enteral administration warm-blooded animals This suggests the patent is positioned for veterinary or animal health markets rather than human-specific NDA/ANDA workflows. Solid-form strategy matters for commercial launch readiness Any commercial scale crystallisation step that controls: hydration state residual water exposure humidity during handling drying step endpoint can be the difference between avoiding and triggering claims 1–3 and 8. Key Takeaways US 4,711,880 protects a specific class of water-of-crystallisation-containing crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate, with layered narrowing via (i) ~24.1–24.5 wt% water, (ii) pentahydrate identity, (iii) crystallisation/drying/RH process windows, and (iv) a detailed XRPD diffraction “fingerprint.” Strongest design-around options are to produce a different hydrate/solid form that fails claim 2 (water content band), claim 3 (not pentahydrate), and/or claim 8 (XRPD mismatch). Process constraints in claims 4–7 create additional infringement and discovery hooks through temperature profiles and humidity exposure logs. Claim 9 expands to enteral animal formulations containing the patented crystalline form. FAQs 1) What crystalline solid identifiers matter most for US 4,711,880 infringement? XRPD match under Guinier-de-Wolff with copper Kα (claim 8) and measured water content (~24.1–24.5 wt%, claim 2), plus pentahydrate identity (claim 3). 2) Can a competitor avoid claim 2 by shifting residual water slightly? Yes, shifting water content outside ~24.1–24.5 wt% can avoid claim 2, though claim 1 may still apply if the material remains a water-of-crystallisation crystalline form. 3) If a competitor makes the same pentahydrate via different process conditions, does that avoid claims 5–7? It may avoid the specific “obtainable by” process limitations in claims 5–7, but the presence of the protected crystalline form still risks claims 1–3 and 8. 4) Does claim 9 cover human enteral products? Claim 9 is limited to “warm-blooded animals,” so it is not drafted for a human-only scope. 5) Which claim is most likely to require technical solid-state characterization evidence? Claim 8, because it is anchored to XRPD d-values and relative intensity descriptors. References (APA) United States Patent 4,711,880. More… ↓ ⤷ Start Trial

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Switzerland	3768/84	Aug 06, 1984

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	240832	⤷ Start Trial
Argentina	244696	⤷ Start Trial
Argentina	244697	⤷ Start Trial
Argentina	244698	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Summary for Patent: 4,711,880